← Back to front page
United States · Wires & real time · PR Newswire

Candel Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Candel Therapeutics (CADL)

Published by PR Newswire · United States 33 min ago
Candel Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Candel Therapeutics (CADL)
PR Newswire

Detailed summary

Candel raised $80 million from investors in part to prepare its aglatimagene BLA. On November 12, 2026, the submission slipped to mid-2027 and CADL fell over 26%, prompting an…

Candel raised $80 million from investors in part to prepare its aglatimagene BLA. On November 12, 2026, the submission slipped to mid-2027 and CADL fell over 26%, prompting an investigation into potential securities law violations tied to that BLA timeline.

NEW YORK, Nov. 16, 2026 /PRNewswire/ -- More than 26% of the value of Candel Therapeutics (NASDAQ: CADL) shares was wiped out after the Company announced on November 12, 2026 that it now expects to submit its Biologics License Application (BLA) for aglatimagene in localized prostate cancer in mid-2027 instead of the fourth quarter of 2026. If you bought CADL and are now holding a loss, you are encouraged to submit your CADL loss details today or contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.

That BLA was a stated use of investor money. In December 2024, Candel announced an $80 million public offering. In a Form 8-K, it said it intended to use the net proceeds to continue development of its product candidates, "including preparing submission of a Biologics License Application for CAN-2409 in prostate cancer." CAN-2409 is aglatimagene.

The same November 12 disclosure came with a new $50 million at-the-market equity program. Candel's Form 10-Q, also dated November 12, stated: "We will require additional capital to commercialize aglatimagene in early localized prostate cancer." The Company cited "timelines associated with certain assay refinement" and ongoing FDA dialogue for the delay. The investigation concerns whether Candel may not have adequately disclosed BLA timing risks before CADL shares fell.

Lost money on CADL? Start your free CADL loss review or call (212) 363-7500.

Levi & Korsinsky, LLP -- Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Billions recovered.

Q: How much did CADL stock drop?A: Shares fell approximately $2.19, or about 26% after the Company disclosed on November 12, 2026 that it now expects to submit its aglatimagene BLA in mid-2027…

Q…

Opening of the article, excerpted from PR Newswire. To read the rest, open the article on the publisher's site.

Read the full article on PR Newswire Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.prnewswire.com)

Also worth reading